Abstract
Dyslipidemia and vascular inflammation play critical roles in the onset of acute coronary syndromes including myocardial infarction. Recent advances in cardiovascular medicine demonstrate that lipid-lowering therapy by 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) prevents acute coronary complications, probably by limiting inflammation in atheroma. Although a number of studies have suggested various effects of statins on vascular dysfunction independent of lipid lowering, the clinical benefits of such effects are not established as yet.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
-
Review
MeSH terms
-
Coronary Artery Disease / drug therapy
-
Coronary Artery Disease / pathology
-
Coronary Disease / drug therapy
-
Coronary Disease / metabolism
-
Coronary Disease / physiopathology
-
Endothelial Cells / drug effects
-
Endothelial Cells / metabolism
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
-
Oxidative Stress / drug effects
-
Treatment Outcome
-
Vascular Diseases / drug therapy*
-
Vascular Diseases / metabolism
-
Vascular Diseases / physiopathology
Substances
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors